Healthcare / BiotechnologyKOSDAQ
$7000.00
-70.00 (-0.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $667.4M · quality 29.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$58.9B
P/E
N/A
•EV/EBITDA
27.7x
↑ROE
-15.2%
↓Gross Margin
45.4%
↓Debt/Equity
1.20
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.4%
FCF CAGR
—
FCF margin
2.2%
FCF / Net income
-0.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $30.99B · net income $-4.31B · FCF $667.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $30.99B | $30.99B | $27.22B | $27.94B | $23.64B |
| Net Income | $-4.31B | $-4.31B | $-4.77B | $-8.80B | $-8.51B |
| EBITDA | $2.93B | $2.93B | $3.17B | $148.1M | $-2.83B |
| EPS | -484.00 | -484.00 | -544.00 | -1018.00 | -988.00 |
| Gross Margin | 45.4% | 45.4% | 44.4% | 45.2% | 46.7% |
| Operating Margin | -9.8% | -9.8% | -12.7% | -14.5% | -27.5% |
| Net Margin | -13.9% | -13.9% | -17.5% | -31.5% | -36.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.20 | 1.20 | 1.04 | 1.58 | 0.72 |
| Current Ratio | 0.88 | 0.88 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $667.4M | $667.4M | $3.19B | $-6.07B | $-11.28B |
| Returns | |||||
| ROE | -15.2% | -15.2% | -16.3% | -29.8% | -20.8% |
| Valuation | |||||
| EV/EBITDA | 27.68 | 27.68 | 49.16 | 1338.42 | — |
| P/B | 2.20 | 2.20 | 4.75 | 5.74 | 3.58 |
| Growth & Yield | |||||
| Revenue Growth | 13.9% | 13.9% | -2.6% | 18.2% | — |
| EPS Growth | 11.0% | 11.0% | 46.6% | -3.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-60.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-544.00 → -484.00
Residual
-60.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.